ArticleAdvances in rheumatology (London, England)2026
Correlation between Adalimumab concentration, anti-drug antibody and clinical efficacy in rheumatoid arthritis and ankylosing spondylitis.
Article in Advances in rheumatology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo detect anti-drug antibody (ADA), Neutralizing Antibody (NAb) and Adalimumab (ADL) concentration in Rheumatoid arthritis (RA) and Ankylosing spondylitis (AS) and investigate correlations with clinical efficacy.
methods78 active RA patients, 59 active AS patients and 30 age, sex matched healthy individuals were recruited. The treatment course was 24 weeks with assessments every 12 weeks. ADL concentration, ADA and NAb were measured by enzyme-linked immunosorbent assay (ELISA). SPSS 26.0 was applied for statistical analysis.
resultsThe ADA incidence in AS group was higher than that in RA group after 24 weeks of treatment. The ADL concentration in AS/RA group with ADA was lower than that without ADA after 12/24 weeks of treatment. At 24 weeks of treatment: In RA group, the Remission-Low activity group's ADL concentration was higher than that of the Moderate-Severe activity group, and the ADA positive rate was lower (χ²=4.481, P = 0.034). In AS group, the Remission-Low activity group's ADL concentration was higher than that of the High-Extreme high activity group, and the ADA positive rate was lower (χ²=5.184, P = 0.023). Logistic regression analysis showed that ADA at 12/24 weeks and disease course were risk factors for Moderate-Severe activity status in RA group and High-Extreme high activity status in AS group. In contrast, log₁₀(ADL concentration) at 24 weeks was a protective factor in RA, and log₁₀(ADL concentration) at 12 and 24 weeks were protective factors in AS.
conclusionThe total incidence of ADA, which is almost entirely NAb in RA and AS patients at 24 weeks after ADL treatment, is approximately 20%. AS patients show higher ADA incidence than RA patients. ADA correlates with lower ADL concentration and is closely related to disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.